Patents by Inventor David C. Tully

David C. Tully has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING INFLAMMATORY DISEASES
    Publication number: 20260137706
    Abstract: The present disclosure relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed herein, with the compounds of Formula (I), and pharmaceutically acceptable salts thereof, and the compositions comprising same.
    Type: Application
    Filed: December 5, 2025
    Publication date: May 21, 2026
    Inventors: Mario G. CARDOZO, Zuojun GUO, Robert Joseph MOREAU, Naomi S. RAJAPAKSA, Meera RAO, David C. TULLY, Steffen GREßIES, Kai THEDE, Zachary K. SWEENEY
  • METHODS OF TREATING INFLAMMATORY DISEASES
    Publication number: 20260091026
    Abstract: The present application relates to compounds of Formula (I) and Formula (II), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed herein, with the compounds of Formula (I) or Formula (II), and pharmaceutically acceptable salts of the foregoing, and the compositions comprising same.
    Type: Application
    Filed: December 5, 2025
    Publication date: April 2, 2026
    Inventors: Robert Joseph MOREAU, Naomi S. RAJAPAKSA, David C. TULLY, Mario G. CARDOZO, Zuojun GUO, Meera RAO, Steffen GREßIES, Kai THEDE, Zachary K. SWEENEY
  • IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS
    Publication number: 20250346593
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed herein, with the compounds of Formula (I), and pharmaceutically acceptable salts thereof, and the compositions comprising same.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 13, 2025
    Inventors: Mario G. Cardozo, Zuojun Guo, Robert Joseph Moreau, Naomi S. Rajapaksa, Meera Rao, David C. Tully, Steffen Greßies, Kai Thede, Zachary K. Sweeney
  • LRRK2 INHIBITORS
    Publication number: 20250270209
    Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, or inflammatory bowel disease such as Crohn's disease.
    Type: Application
    Filed: November 8, 2024
    Publication date: August 28, 2025
    Inventors: David C. TULLY, Robert J. MOREAU, Naomi S. RAJAPAKSA, Meera RAO, Zuojun GUO, Mario G. CARDOZO
  • LRRK2 INHIBITORS
    Publication number: 20250066356
    Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, or inflammatory bowel disease such as Crohn's disease.
    Type: Application
    Filed: November 8, 2024
    Publication date: February 27, 2025
    Inventors: Robert J. MOREAU, David C. TULLY, Zuojun GUO, Mario G. CARDOZO, Zachary K. SWEENEY
  • Compounds and compositions for the treatment of parasitic disease
    Patent number: 9963454
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 8, 2018
    Assignee: Novartis AG
    Inventors: Arnab K. Chatterjee, Kelli L. Kuhen, Advait S. Nagle, David C. Tully, Tao Wu
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 9469645
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: October 18, 2016
    Assignee: Novartis AG
    Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE
    Publication number: 20160108051
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Applicant: NOVARTIS AG
    Inventors: Arnab K. Chatterjee, Kelli L. Kuhen, Advait S. Nagle, David C. Tully, Tao Wu
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20150366856
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: July 30, 2015
    Publication date: December 24, 2015
    Applicant: NOVARTIS AG
    Inventors: David C. Tully, Vincent Paul Rucker, Phillip Alper, Daniel Mutnick, Donatella CHIANELLI
  • Compositions and methods for modulating FXR
    Patent number: 9150568
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 6, 2015
    Assignee: NOVARTIS AG
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20140039007
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: February 6, 2014
    Inventors: David C. Tully, Donatella Chianelli
  • COMPOSITIONS AND METHODS FOR MODULATING FXR
    Publication number: 20130331349
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: December 12, 2013
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20130281403
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 24, 2013
    Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
  • Compounds and compositions useful for the treatment of parasitic diseases
    Patent number: 8557801
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: October 15, 2013
    Assignee: IRM LLC
    Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20130261108
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: October 3, 2013
    Applicant: IRM LLC
    Inventors: David C. Tully, Agnes Vidal, Daniel Mutnick, Phillip B. Alper
  • Compounds and compositions as channel activating protease inhibitors
    Patent number: 8338469
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 25, 2012
    Assignee: IRM LLC
    Inventors: David C. Tully, Amab K. Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon
  • Compounds and compositions as channel activating protease inhibitors
    Patent number: 8293915
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: October 23, 2012
    Assignee: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Zhiwei Wang
  • Compounds and compositions as cathepsin S inhibitors
    Patent number: 8268996
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: September 18, 2012
    Assignee: IRM LLC
    Inventors: Hong Liu, David C. Tully, Arnab Chatterjee, Phillip B. Alper, David H. Woodmansee, Daniel Mutnick
  • Organic Compounds
    Publication number: 20120208882
    Abstract: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: February 14, 2012
    Publication date: August 16, 2012
    Inventors: Henry Luke Danahay, Darren Mark LeGrand, David C. Tully, Jennifer Leslie Harris, Silvia Heuerding, Dilraj Singh, Janet Catherine Maas, Juergen Roettele, Jean-Louis Reber, Stéphanie Monnier
  • COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4)
    Publication number: 20120077854
    Abstract: The present invention relates to compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4). In particular, the present invention provides compounds having Formula (1) or (2) (Formulae (1), (2)); wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, Y4 and m are as defined above.
    Type: Application
    Filed: April 13, 2010
    Publication date: March 29, 2012
    Inventors: Hank Michael James Petrassi, David C. Tully, Brian T. Masick, Bao Nguyen